Exhibit 99.1 Affimed N.V. Unaudited consolidated statements of comprehensive loss (in € thousand) | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------|-------|-------------------------------------------|-----------------| | | Note | For the three months March \n2023 | ended 31 \n2022 | | Revenue | 3 | 4,510 | 8,006 | | Other income – net | | 410 | 284 | | Research and development expenses | | (29,531) | (18,379) | | General and administra ...

Affimed N.V. (NASDAQ:AFMD) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Conference Call Participants Daina Graybosch - SVB Securities Srikripa Devarakonda - Truist Maurice Raycroft - Jefferies Li Watsek - Cantor Operator Good day, ladies and gentlemen. Thank you for sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...

Exhibit 99.1 PRESS RELEASE Affimed Reports 2022 Financial Results and Operational Progress Heidelberg, Germany, March 23, 2023 – Affimed N.V. (Nasdaq: AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress. "During 2022, we presented data across our pipeline that show our innate cell enga ...

Affimed N.V. (NASDAQ:AFMD) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Alex Fudukidis - Director of IR Adi Hoess - CEO Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - COO Angus Smith - CFO Conference Call Participants Srikripa Devarakonda - Truist Maurice Raycroft - Jefferies Daina Graybosch - SVB Securities Do Kim - Piper Sandler Li Watsek - Cantor James Shin - Wells Fargo Yale Jen - Laidlaw & Company Zhiqiang ...

Affimed NV (NASDAQ:AFMD) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Alexander Fudukidis - Head, IR Adi Hoess - CEO Angus Smith - CFO Andreas Harstrick - Chief Medical Officer Conference Call Participants Daina Graybosch - SVB Securities Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald & Co. Zhiqiang Shu - Berenberg Yale Jen - Laidlaw & Company Bijan Mekoba - Stifel, Nicolaus & Company Operator Good day, everyone, and welcome to the Affimed Second Quarter 2022 ...

Affimed N.V. (NASDAQ:AFMD) Q1 2022 Results Conference Call June 1, 2022 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - Chief Operating Officer Angus Smith - Chief Financial Officer Conference Call Participants Daina Graybosch - SVB Securities Kripa Devarakonda - Truist Securities Maury Raycroft - Jefferies Li Watsek - Cantor Brad Canino - ...